Pesquisar
VolitionRX Ltd
VNRXAdicionar à lista de desejos
1.400USD
+0.020+1.47%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
555.14KValor de mercado
PerdaP/L TTM
Mais detalhes de VolitionRX Ltd Empresa
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Informações de VolitionRX Ltd
Código da empresaVNRX
Nome da EmpresaVolitionRX Ltd
Data de listagemFeb 06, 2015
CEOButera (Salvatore Thomas)
Número de funcionários85
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 06
Endereço1489 West Warm Springs Road
CidadeHENDERSON
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal89014
Telefone17024251561
Sitehttps://volition.com/
Código da empresaVNRX
Data de listagemFeb 06, 2015
CEOButera (Salvatore Thomas)
Executivos da empresa VolitionRX Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
18.19K
-3.54%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
16.56K
-2.28%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
13.70K
-2.65%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
12.24K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Perguntas frequentes
Quem são os cinco principais acionistas de VolitionRX Ltd?
Os cinco principais acionistas de VolitionRX Ltd são: Mr. Guy Archibald Innes
Quantas instituições possuem ações da VolitionRX Ltd (VNRX)?
Em 2026Q1, 66 instituições possuíam ações da VolitionRX Ltd, com valor de mercado aproximado de 1.13M, representando 13.93% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -209799.00.